Hanmi Pharm128940.KS

關於Hanmi Pharm

Hanmi Pharmaceutical built its reputation on incrementally modified drugs, improved formulations and fixed-dose combinations of existing medicines, which fund one of Korea's larger pharmaceutical research programs. Domestic mainstays include combination therapies for hypertension and high cholesterol, some marketed with multinational partners. The company's Lapscovery platform, designed to extend the half-life of biologic drugs, underpins a pipeline in metabolic disease and oncology that has generated a series of out-licensing agreements with global drugmakers. Hanmi also operates a Beijing-based subsidiary serving the Chinese market, and it is controlled by Hanmi Science, the listed family holding company.

Licensing economics give the story its structural texture for foreign investors: upfront and milestone payments arrive unevenly, and returned or terminated partnerships have historically been a feature of the model, making pipeline breadth a key checkpoint. The domestic base is steadier but operates under government drug-price controls. Ownership through a listed holding company, with the founding family's stakes concentrated above, keeps succession and inheritance-related share movements on the governance agenda. The Chinese subsidiary ties part of the earnings picture to that market's demand patterns and regulatory environment.

Pharmacist Lim Sung-ki founded Hanmi in 1973, building it on skillfully improved versions of existing medicines and an aggressive domestic sales culture. The company established Beijing Hanmi in 1996, unusually early for a Korean drugmaker in China, and poured generic profits into research from the 2000s onward. In 2010 the business split, creating the holding company now called Hanmi Science above the listed operating company. A wave of licensing agreements with global drugmakers in the mid-2010s made Hanmi a symbol of Korean pharmaceutical ambition, and in 2022 its long-acting neutropenia treatment won U.S. approval. The founder died in 2020.

Hanmi funds discovery with a self-reliant commercial engine: rather than importing multinationals' drugs for resale, it emphasizes products it develops and manufactures itself, led by fixed-dose combination therapies that command loyal prescribing in hypertension and cholesterol care. Its Paltan complex houses formulation research and production, while a biologics plant supports the long-acting Lapscovery platform. Out-licensing supplies a second economic layer: partners pay upfront fees, milestones tied to trial progress, and royalties on eventual sales, income that arrives unevenly but requires no overseas sales force. Beijing Hanmi sells pediatric and digestive medicines through its own Chinese network, an asset few Korean peers replicate.

公司簡介由LineVest編輯部撰寫。屬新聞報導，非投資建議。 委託撰寫Hanmi Pharm的DART完整報告 →